Sangamo reports Q4 net loss $52M, cash down to $307.5M; halts sickle cell investment, seeks partner

SANGAMO THERAPEUTICS, INC

2022-FY EPS reported -$1.25 revenue$111,299,000

Q4 2022 net loss $52.0M ($0.32/share) vs $37.5M loss in Q4 2021.
Full year 2022 net loss $192.3M ($1.25/share) vs $178.3M in 2021.
Cash and marketable securities $307.5M at Dec 31, 2022, down from $464.7M a year ago.
2023 GAAP operating expense guidance $310-330M; non-GAAP $275-295M.
Discontinuing material investments in sickle cell program; seeking collaboration partner for Phase 3.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SANGAMO THERAPEUTICS, INC reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 22, 2023, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022 (the “Press Release”).

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

SANGAMO THERAPEUTICS, INC filing history →

Source: SEC EDGAR

accession 0001628280-23-004552

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.